Email Sign-Up
 
63 results found
Filter Filters icon
Apply

Article

PARP inhibitors for BRCA-positive breast cancer

PARP inhibitors are targeted therapies used to treat certain breast, ovarian, pancreatic, and prostate cancers. In breast cancer, PARP inhibitors are FDA approved for people who were born with a ...

Article

Olaparib

Olaparib (Lynparza) is a targeted therapy approved by the Food and Drug Administration that is used to treat early-stage or metastatic breast cancer that is either hormone receptor-positive and ...

Article

Talazoparib

Talazoparib (Talzenna) is a targeted therapy for metastatic or locally advanced breast cancer that is hormone receptor-positive and HER2-negative, or triple-negative, in people with an inherited ...

Article

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine (Kadcyla) is the targeted therapy trastuzumab (Herceptin) with the chemotherapy medicine emtansine attached. It may also be called T-DM1.

Article

Aromatase inhibitors

The aromatase inhibitors, or AIs, are a class of medicines that reduce the risk of breast cancer returning in postmenopausal women with hormone receptor-positive, early-stage breast cancer.

Article

Sacituzumab govitecan

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with metastatic, ...

Article

Tucatinib

Tucatinib (Tukysa) is a tyrosine kinase inhibitor used to treat metastatic, HER2-postive breast cancer. It is given with another targeted therapy, trastuzumab (Herceptin), and the chemotherapy ...

Article

Trastuzumab

The medicine trastuzumab (Herceptin and biosimilars) is the most common medicine used to treat HER2-positive breast cancer. It is a monoclonal antibody, a medicine made in a lab that attacks a ...

Article

Pertuzumab

Pertuzumab (Perjeta) is a targeted therapy used to treat early-stage and metastatic HER2-positive breast cancer. Pertuzumab is a monoclonal antibody, a type of medicine made in a lab that targets ...

Article

Neratinib

Neratinib (Nerlynx) is a targeted therapy for people with HER2-positive breast cancer. It is the first medicine for people with HER2-positive breast cancer approved as extended therapy, meaning ...